Coordinator of the Gene Transfer Laboratory of the Ribeirão Preto Blood Center (FMRP/USP). He holds a Bachelor's degree (2010) in Biological Sciences from the School of Philosophy, Sciences and Letters of Ribeirão Preto (USP). He holds a Master's degree in Biomedical Research (2012) and a PhD in Stem Cells and Cell Therapy (2016) from the School of Medicine of Ribeirão Preto (USP). He completed his postdoctoral studies at thematic unit 935 of INSERM (France), focusing on the biology of leukemic stem cells (2019). He is currently developing basic and applied studies in advanced cell therapy, focusing on the development of genetically modified T cells for the treatment of neoplasms. He has regulatory experience in the area of #8203;#8203;advanced therapies, as he was the director of preclinical studies that supported the approval of the clinical trial (CARTHEDRALL-01), which aims to investigate anti-CD19 CAR-T cells in the treatment of leukemia and lymphoma. He also coordinates the development of analytical methods for quality control for CAR-T cells based on digital PCR. Currently, research efforts are directed at understanding the intrinsic and extrinsic mechanisms that regulate the antitumor activity of genetically modified T cells and developing methods that facilitate access and increase the efficacy of these therapies. He is a master's and doctoral advisor in the postgraduate program in Clinical Oncology, Stem Cells and Cell Therapy at the Ribeirão Preto School of Medicine (USP). (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Adoptive transfer of T lymphocytes expressing chimeric antigen receptors (CARs) has demonstrated impressive remission rates against B cell malignancies. However, many cancer patients experience refractoriness or disease relapse due to functional exhaustion of CAR-T cells. Therefore, it is desirable that the final cellular product is enriched with naïve T cells (TN), which have a greater c…
Since the approval of the first cell therapy product for the treatment of neoplasms with CAR-T lymphocytes in 2017, impressive clinical results have been achieved. However, even though this type of immunotherapy is increasingly becoming a form of cancer treatment, especially in hematological tumors, there are several limitations to its use. One of the main restrictions for expanding the c…
Despite the remarkable clinical results, the autologous nature of CAR-T cell manufacturing process restricts the access of patients to this therapy. Therefore, one of the next frontiers in the field is to develop an allogeneic, 'off-the-shelf', CAR-T cell therapy. Initial studies have already provided a proof-of-concept of such "universal" therapy by knocking out the T cell receptor (TCR)…
Adoptive transfer of T lymphocytes expressing chimeric antigen receptors (CARs) against CD19 glycoprotein has already shown long-lasting clinical remission in patients with some types of B-cell lymphomas and leukemias. However, in patients with chronic lymphoid leukemia, treatment response is restricted to about 20% of patients and there is no evidence of therapeutic efficacy in solid tum…
Cell therapy using T cells expressing chimeric antigen receptors (CARs) has already revolutionized the treatment of some B-cell leukemias and lymphomas. However, for other hematological malignancies and solid tumors, the long-term clinical response rate is low (~ 20%) or nonexistent. Recent studies indicate that the main causes of these failure cases are the anergy and low persistence of …
(Only some records are available in English at this moment)
The use of autologous T cells expressing chimeric antigen receptors (CAR) has revolutionized the therapy of B-cell neoplasms. However, the use of allogeneic CAR-T cells has numerous advantages over this autologous approach, such as the immediate availability of cryopreserved batches for infusion, standardization of the final cell product, time for multiple genetic modifications in cells, …
| 2 / 2 | Ongoing scholarships in Brazil |
| 4 / 4 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 7 / 7 | All Scholarships |
| Associated processes | |
CV Lattes
ORCID